In CML cell lines, RUNX1 mutations induce phenotypic, transcriptional, and drug sensitivity profiles similar to RUNX1mut BP-CML patients. This evidence concerns the gene RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive.